NCT05379790View on ClinicalTrials.gov

Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

November 25, 2024

Study Completion Date

February 17, 2025

Conditions
Gastric CancerPeritoneal Metastases
Interventions
DRUG

Irinotecan

3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.

DRUG

CAPOX

Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.

Trial Locations (2)

3015 GD

Erasmus MC, Rotterdam

Unknown

Catharina Hospital, Eindhoven

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT05379790 - Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin | Biotech Hunter | Biotech Hunter